ClinicalTrials.gg
CompletedNCT00980655Updated Dec 20, 2018Results posted

Study to Evaluate 13 Valent Pneumococcal Conjugate Vaccine (13vPnC) Vaccine Followed by 23-valent Pneumococcal Polysaccharide Vaccine (23vPS) Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients

A Phase 3 interventional study of 13vPnC and 23vPS in Vaccines, Pneumococcal Conjugate Vaccine, sponsored by Pfizer. Completed at 47 sites in 10 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2018-12-20.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
251
Allocation
Non-randomized
Ages
2 Years and older
Sex
All
01

Study summary

People who have received an allogeneic hematopoetic stem cell transplant (HSCT) are more likely than other people to get ill from a germ called Streptococcus pneumoniae. Most people who have had a stem cell transplant are offered a vaccine called 23-valent pneumococcal polysaccharide vaccine (23vPS) to help protect against this germ. The purpose of this study is to evaluate the immune response in HSCT recipients who receive a 13 valent pneumococcal vaccine (13vPnC) followed by 23vPS.

02

Conditions studied

  • Vaccines, Pneumococcal Conjugate Vaccine
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subject >=2 years of age.
  • HSCT for hematologic disorder.
  • Allogeneic HSCT with full myeloablative conditioning or reduced intensity conditioning.
  • Allogeneic HSCT approximately 3 to 6 months (91 days to 203 days) before enrollment.
  • Stable engraftment ( (ANC) >1000/µL; count >50,000/µL).
  • Complete hematologic remission of underlying disease with very good partial remission (VGPR) acceptable in the case of lymphoma and myeloma.
  • Subject or parent/legal guardian expected to be available for the entire study and can be contacted by telephone.
  • Subject or parent/legal guardian must be able to complete an electronic diary (e-diary) and complete all relevant study procedures during study participation.
  • Hematological recovery as defined by ANC >1000/µL; platelet count >50,000/µL.
  • All female and male subjects who are biologically capable of having children must agree to abstinence or commit to the use of a reliable method of from signing of the ICF until for 3 months after the last vaccination.
  • Negative urine pregnancy test for all female subjects of child bearing potential.

Exclusion criteria

Exclusion Criteria:

  • HSCT.
  • Receipt of donor lymphocyte infusions during the 28 days preceding enrollment.
  • Uncontrolled that in the opinion of the investigator would prevent the subject from participating in the study.
  • Lansky/ Score \<=60%.
  • Receipt of plasma products or immunoglobulins during the 60 days preceding enrollment.
  • Receipt of rituximab since HSCT.
  • Receipt of chemotherapy for relapse of underlying malignant disease since HSCT.
  • (HIV) infection.
  • Lymphoproliferative disorder since HSCT.
  • Chronic illnesses with cardiac, pulmonary, renal, or liver failure that in the opinion of the investigator would prevent the subject participating in the study.
  • Vaccination with any licensed or experimental pneumococcal vaccine since HSCT.
  • Previous anaphylactic reaction to any vaccine or vaccine-related component.
  • Bleeding diathesis or condition associated with prolonged bleeding time that would in the opinion of the investigator contraindicate intramuscular injection.
  • Participation in another study with ongoing use of an unlicensed product from 28 days before study enrollment until the end of the study.
  • Participation in another study with ongoing use of a licensed investigational product that in the opinion of the investigator would interfere with the evaluation of the study objectives.
  • Permanent residence in a nursing home or other residential care facility.
  • Pregnant or breastfeeding female subject.
  • Subject who is a direct relative (child, grandchild, parent, or grandparent) of study personnel, or is a member of the study personnel.
  • Receipt of advanced therapy medicinal products (ATMP) including gene therapy products, somatic cell therapy products, and tissue engineered products at any time before enrollment.
  • If information is available, - previous allergic or anaphylactic reaction to any vaccine or vaccine-related component in a stem cell donor.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Masking
None (open label)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    1

    Biological: 13vPnC · Biological: 23vPS

Interventions

  • Biological13vPnC

    0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5. Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose.

  • Biological23vPS

    0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.

06

What researchers measure

Primary outcomes

  1. Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in All Participants

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.

    Time frame: Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 3

Secondary outcomes

  1. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 3 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: 1 month after 13vPnC Dose 3

  2. Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants

    Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 4 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

    Time frame: 1 month after 13vPnC Dose 4

  3. Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.

    Time frame: Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 3

  4. Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 4 blood draws.

    Time frame: Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 4

  5. Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants

    GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both after 13vPnC Dose 3 and after 13vPnC Dose 4 blood draws.

    Time frame: 1 month after 13vPnC Dose 3, 1 month after 13vPnC Dose 4

Other outcomes

  1. Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 1

    Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).

    Time frame: Within 14 days after 13vPnC Dose 1

  2. Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 2

    Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).

    Time frame: Within 14 days after 13vPnC Dose 2

  3. Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 3

    Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).

    Time frame: Within 14 days after 13vPnC Dose 3

  4. Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 4

    Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).

    Time frame: Within 14 days after 13vPnC Dose 4

  5. Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 1

    Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).

    Time frame: Within 14 days after 13vPnC Dose 1

  6. Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 2

    Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).

    Time frame: Within 14 days after 13vPnC Dose 2

  7. Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 3

    Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).

    Time frame: Within 14 days after 13vPnC Dose 3

  8. Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 4

    Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).

    Time frame: Within 14 days after 13vPnC Dose 4

07

Results

Posted Apr 21, 2014

Participant flow

Participant flow — Overall Study
Milestone13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)
Started61190
Vaccinated 13vpnc dose 159188
Vaccinated 13vpnc dose 255176
Vaccinated 13vpnc dose 354167
Vaccinated 13vpnc dose 446146
Vaccinated 23vps dose45140
Completed45139
Not completed1651
Withdrew: Adverse event1331
Withdrew: Death07
Withdrew: Protocol violation27
Withdrew: Withdrawal by subject04
Withdrew: Lost to follow-up01
Withdrew: Parent/legal guardian request10
Withdrew: Other01

Outcome measures

PrimaryGeometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in All Participants

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. Confidence interval (CI) for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.

Time frame:
Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 3
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in All Participants
fold rise13vPnC, 23vPS (All Participants)
Serotype 1 (n=191)17.96 (13.63 to 23.66)
Serotype 3 (n=192)5.07 (3.98 to 6.46)
Serotype 4 (n=193)23.85 (17.61 to 32.30)
Serotype 5 (n=194)2.99 (2.46 to 3.63)
Serotype 6A (n=195)5.35 (4.18 to 6.85)
Serotype 6B (n=192)5.18 (3.99 to 6.74)
Serotype 7F (n=195)10.28 (8.15 to 12.96)
Serotype 9V (n=196)5.76 (4.63 to 7.17)
Serotype 14 (n=197)4.95 (3.72 to 6.58)
Serotype 18C (n=196)8.22 (6.36 to 10.62)
Serotype 19A (n=196)3.90 (3.10 to 4.89)
Serotype 19F (n=195)6.73 (5.15 to 8.78)
Serotype 23F (n=197)8.01 (6.11 to 10.51)
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95 percent (%) CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 3 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
1 month after 13vPnC Dose 3
Reported as:
Geometric mean · microgram per milliliter (mcg/mL)
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 3 in Pediatric, Adult and All Participants
microgram per milliliter (mcg/mL)13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1 (n=49, 147, 196)3.52 (2.38 to 5.19)2.05 (1.53 to 2.76)2.35 (1.84 to 2.99)
Serotype 3 (n=49, 147, 196)1.60 (1.13 to 2.26)0.62 (0.49 to 0.79)0.79 (0.64 to 0.97)
Serotype 4 (n=49, 147, 196)4.13 (2.68 to 6.36)1.78 (1.35 to 2.34)2.20 (1.73 to 2.78)
Serotype 5 (n=48, 149, 197)4.18 (2.95 to 5.91)2.00 (1.60 to 2.51)2.39 (1.97 to 2.91)
Serotype 6A (n=49, 148, 197)7.61 (5.16 to 11.23)3.31 (2.53 to 4.33)4.07 (3.25 to 5.11)
Serotype 6B (n=48, 147, 195)6.29 (3.88 to 10.19)3.00 (2.25 to 3.98)3.60 (2.81 to 4.61)
Serotype 7F (n=48, 149, 197)7.34 (5.12 to 10.53)3.92 (3.08 to 5.00)4.57 (3.72 to 5.61)
Serotype 9V (n=49, 149, 198)4.17 (3.01 to 5.78)2.44 (1.93 to 3.10)2.79 (2.29 to 3.40)
Serotype 14 (n=49, 149, 198)6.22 (4.03 to 9.61)5.99 (4.35 to 8.26)6.05 (4.65 to 7.86)
Serotype 18C (n=49, 148, 197)4.17 (2.90 to 5.98)3.04 (2.37 to 3.91)3.29 (2.67 to 4.05)
Serotype 19A (n=49, 148, 197)8.26 (5.86 to 11.65)4.77 (3.77 to 6.04)5.47 (4.49 to 6.67)
Serotype 19F (n=49, 148, 197)5.80 (3.80 to 8.84)3.48 (2.69 to 4.50)3.95 (3.17 to 4.93)
Serotype 23F (n=49, 149, 198)6.74 (4.12 to 11.05)3.87 (2.85 to 5.26)4.44 (3.42 to 5.77)
SecondaryGeometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants

Antibody GMC for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) for pediatric, adult and all participants are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. Geometric means were calculated using all participants with available data for 1 month after 13vPnC Dose 4 blood draw. CI for GMC are back transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations.

Time frame:
1 month after 13vPnC Dose 4
Reported as:
Geometric mean · mcg/mL
Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants
mcg/mL13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1 (n=38, 123, 161)8.75 (5.64 to 13.59)4.67 (3.37 to 6.47)5.41 (4.13 to 7.10)
Serotype 3 (n=38, 123, 161)1.23 (0.89 to 1.70)0.91 (0.71 to 1.17)0.97 (0.79 to 1.20)
Serotype 4 (n=36, 124, 160)8.41 (5.15 to 13.72)4.56 (3.31 to 6.27)5.23 (3.99 to 6.86)
Serotype 5 (n=38, 122, 160)8.43 (6.07 to 11.70)5.57 (4.28 to 7.26)6.15 (4.95 to 7.64)
Serotype 6A (n=37, 122, 159)16.33 (10.59 to 25.16)12.23 (8.81 to 16.98)13.08 (9.99 to 17.13)
Serotype 6B (n=38, 124, 162)18.13 (11.15 to 29.47)12.13 (8.63 to 17.06)13.33 (10.04 to 17.70)
Serotype 7F (n=38, 124, 162)10.37 (7.36 to 14.61)8.26 (6.33 to 10.78)8.71 (7.00 to 10.83)
Serotype 9V (n=37, 124, 161)7.78 (5.21 to 11.61)5.09 (3.93 to 6.59)5.61 (4.50 to 6.98)
Serotype 14 (n=37, 124, 161)16.04 (10.04 to 25.63)12.24 (9.09 to 16.47)13.02 (10.13 to 16.74)
Serotype 18C (n=38, 122, 160)6.54 (4.04 to 10.59)6.69 (5.01 to 8.93)6.65 (5.20 to 8.51)
Serotype 19A (n=37, 124, 161)16.94 (11.05 to 25.98)12.99 (9.78 to 17.26)13.81 (10.88 to 17.52)
Serotype 19F (n=38, 123, 161)19.96 (12.19 to 32.68)13.69 (9.93 to 18.88)14.96 (11.42 to 19.61)
Serotype 23F (n=38, 123, 161)16.65 (10.73 to 25.82)12.68 (8.82 to 18.22)13.52 (10.07 to 18.15)
SecondaryGeometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 3 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 3 blood draws.

Time frame:
Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 3
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 3 in Pediatric and Adult Participants
fold rise13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)
Serotype 1 (n=48, 143)27.64 (16.75 to 45.62)15.54 (11.20 to 21.56)
Serotype 3 (n=48, 144)7.58 (4.74 to 12.13)4.43 (3.35 to 5.88)
Serotype 4 (n=49, 144)40.83 (23.84 to 69.95)19.86 (13.83 to 28.52)
Serotype 5 (n=47, 147)4.11 (2.86 to 5.90)2.70 (2.15 to 3.39)
Serotype 6A (n=48, 147)7.49 (4.79 to 11.72)4.79 (3.57 to 6.44)
Serotype 6B (n=47, 145)6.02 (3.79 to 9.55)4.94 (3.60 to 6.77)
Serotype 7F (n=48, 147)14.65 (9.63 to 22.28)9.15 (6.95 to 12.05)
Serotype 9V (n=48, 148)7.64 (5.40 to 10.82)5.26 (4.02 to 6.87)
Serotype 14 (n=49, 148)5.01 (2.83 to 8.86)4.92 (3.53 to 6.87)
Serotype 18C (n=49, 147)12.59 (7.84 to 20.21)7.13 (5.27 to 9.65)
Serotype 19A (n=49, 147)5.04 (3.38 to 7.51)3.58 (2.72 to 4.70)
Serotype 19F (n=49, 146)7.66 (4.67 to 12.57)6.44 (4.69 to 8.85)
Serotype 23F (n=49, 148)9.73 (5.79 to 16.34)7.52 (5.46 to 10.35)
SecondaryGeometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from before 13vPnC Dose 1 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both before 13vPnC Dose 1 and after 13vPnC Dose 4 blood draws.

Time frame:
Before 13vPnC Dose 1 (pre-vaccination), 1 month after 13vPnC Dose 4
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From Before 13vPnC Dose 1 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants
fold rise13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1 (n=37, 120, 157)70.66 (39.20 to 127.36)35.81 (25.06 to 51.18)42.03 (30.94 to 57.11)
Serotype 3 (n=37, 120, 157)5.88 (3.25 to 10.61)6.41 (4.74 to 8.66)6.28 (4.81 to 8.19)
Serotype 4 (n=36, 121, 157)90.31 (48.05 to 169.77)47.47 (32.09 to 70.22)55.02 (39.39 to 76.85)
Serotype 5 (n=37, 119, 156)7.76 (4.81 to 12.51)7.29 (5.32 to 9.99)7.40 (5.69 to 9.63)
Serotype 6A (n=36, 121, 157)15.62 (9.63 to 25.34)17.02 (11.95 to 24.23)16.90 (12.47 to 22.34)
Serotype 6B (n=37, 122, 159)16.90 (9.76 to 29.25)20.09 (13.94 to 28.94)19.29 (14.22 to 26.18)
Serotype 7F (n=38, 123, 161)19.18 (11.75 to 31.33)18.69 (13.70 to 25.50)18.81 (14.48 to 24.43)
Serotype 9V (n=36, 122, 158)14.90 (9.55 to 23.25)11.13 (8.27 to 14.99)11.90 (9.27 to 15.27)
Serotype 14 (n=37, 123, 160)12.61 (6.47 to 24.56)9.69 (6.80 to 13.80)10.30 (7.55 to 14.03)
Serotype 18C (n=38, 121, 159)21.22 (12.05 to 37.36)14.40 (10.17 to 20.41)15.80 (11.76 to 21.24)
Serotype 19A (n=37, 123, 160)11.46 (7.22 to 18.20)9.52 (6.90 to 13.12)9.94 (7.61 to 12.98)
Serotype 19F (n=38, 120, 158)29.31 (16.63 to 51.64)25.63 (17.56 to 37.43)26.47 (19.31 to 36.29)
Serotype 23F (n=38, 122, 160)25.37 (14.69 to 43.83)23.02 (15.63 to 33.92)23.56 (17.11 to 32.45)
SecondaryGeometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants

GMFR for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from 1 month after 13vPnC Dose 3 to 1 month after 13vPnC Dose 4 were computed using the logarithmically transformed assay results. CI for GMFR were back transformations of a CI based on the Student t distribution for the mean logarithm of the mean fold rise. GMFRs were calculated using all participants with available data from both after 13vPnC Dose 3 and after 13vPnC Dose 4 blood draws.

Time frame:
1 month after 13vPnC Dose 3, 1 month after 13vPnC Dose 4
Reported as:
Geometric mean · fold rise
Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 3 to 1 Month After 13vPnC Dose 4 in Pediatric, Adult and All Participants
fold rise13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Serotype 1 (n=37, 119, 156)2.80 (1.99 to 3.95)2.16 (1.65 to 2.82)2.30 (1.85 to 2.86)
Serotype 3 (n=37, 119, 156)0.88 (0.64 to 1.22)1.32 (1.07 to 1.62)1.20 (1.01 to 1.43)
Serotype 4 (n=35, 121, 156)2.19 (1.51 to 3.19)2.32 (1.88 to 2.86)2.29 (1.91 to 2.74)
Serotype 5 (n=37, 119, 156)2.25 (1.74 to 2.93)2.43 (1.94 to 3.06)2.39 (1.99 to 2.87)
Serotype 6A (n=36, 119, 155)2.36 (1.87 to 2.99)3.06 (2.35 to 3.98)2.88 (2.34 to 3.55)
Serotype 6B (n=37, 120, 157)2.96 (2.09 to 4.19)3.10 (2.44 to 3.95)3.07 (2.51 to 3.75)
Serotype 7F (n=36, 121, 157)1.51 (1.08 to 2.11)1.83 (1.47 to 2.29)1.75 (1.46 to 2.11)
Serotype 9V (n=36, 121, 157)2.08 (1.43 to 3.03)1.82 (1.48 to 2.23)1.88 (1.57 to 2.24)
Serotype 14 (n=36, 121, 157)2.50 (1.65 to 3.80)1.68 (1.32 to 2.13)1.84 (1.50 to 2.26)
Serotype 18C (n=37, 118, 155)1.64 (1.24 to 2.16)1.87 (1.54 to 2.28)1.81 (1.54 to 2.13)
Serotype 19A (n=36, 121, 157)2.25 (1.60 to 3.17)2.33 (1.91 to 2.85)2.31 (1.95 to 2.74)
Serotype 19F (n=37, 120, 157)3.50 (2.15 to 5.68)3.65 (2.90 to 4.59)3.61 (2.94 to 4.44)
Serotype 23F (n=37, 120, 157)2.49 (1.72 to 3.61)2.59 (2.04 to 3.30)2.57 (2.10 to 3.14)
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 1

Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).

Time frame:
Within 14 days after 13vPnC Dose 1
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 1
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Redness: any (n = 38, 130, 168)21.1 (9.6 to 37.3)11.5 (6.6 to 18.3)13.7 (8.9 to 19.8)
Redness: mild (n = 38, 130, 168)15.8 (6.0 to 31.3)10.8 (6.0 to 17.4)11.9 (7.4 to 17.8)
Redness: moderate (n = 37, 128, 165)10.8 (3.0 to 25.4)1.6 (0.2 to 5.5)3.6 (1.3 to 7.7)
Redness: severe (n = 37, 128, 165)0.0 (0.0 to 9.5)0.0 (0.0 to 2.8)0.0 (0.0 to 2.2)
Swelling: any (n = 40, 130, 170)25.0 (12.7 to 41.2)11.5 (6.6 to 18.3)14.7 (9.7 to 20.9)
Swelling: mild (n = 39, 130, 169)10.3 (2.9 to 24.2)10.8 (6.0 to 17.4)10.7 (6.4 to 16.3)
Swelling: moderate (n = 39, 128, 167)20.5 (9.3 to 36.5)0.8 (0.0 to 4.3)5.4 (2.5 to 10.0)
Swelling: severe (n = 37, 128, 165)0.0 (0.0 to 9.5)0.8 (0.0 to 4.3)0.6 (0.0 to 3.3)
Pain: any (n = 51, 171, 222)78.4 (64.7 to 88.7)73.1 (65.8 to 79.6)74.3 (68.1 to 79.9)
Pain: mild (n = 48, 169, 217)68.8 (53.7 to 81.3)69.8 (62.3 to 76.6)69.6 (63.0 to 75.6)
Pain: moderate (n = 42, 138, 180)45.2 (29.8 to 61.3)22.5 (15.8 to 30.3)27.8 (21.4 to 34.9)
Pain: severe (n = 37, 129, 166)5.4 (0.7 to 18.2)2.3 (0.5 to 6.6)3.0 (1.0 to 6.9)
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 2

Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).

Time frame:
Within 14 days after 13vPnC Dose 2
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 2
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Redness: any (n = 28, 109, 137)42.9 (24.5 to 62.8)16.5 (10.1 to 24.8)21.9 (15.3 to 29.8)
Redness: mild (n = 26, 108, 134)34.6 (17.2 to 55.7)15.7 (9.4 to 24.0)19.4 (13.1 to 27.1)
Redness: moderate (n = 26, 103, 129)26.9 (11.6 to 47.8)1.9 (0.2 to 6.8)7.0 (3.2 to 12.8)
Redness: severe (n = 24, 103, 127)4.2 (0.1 to 21.1)1.0 (0.0 to 5.3)1.6 (0.2 to 5.6)
Swelling: any (n = 28, 105, 133)35.7 (18.6 to 55.9)14.3 (8.2 to 22.5)18.8 (12.5 to 26.5)
Swelling: mild (n = 26, 105, 131)15.4 (4.4 to 34.9)14.3 (8.2 to 22.5)14.5 (9.0 to 21.7)
Swelling: moderate (n = 26, 102, 128)26.9 (11.6 to 47.8)0.0 (0.0 to 3.6)5.5 (2.2 to 10.9)
Swelling: severe (n = 24, 102, 126)0.0 (0.0 to 14.2)0.0 (0.0 to 3.6)0.0 (0.0 to 2.9)
Pain: any (n = 40, 154, 194)77.5 (61.5 to 89.2)74.7 (67.0 to 81.3)75.3 (68.6 to 81.2)
Pain: mild (n = 36, 148, 184)66.7 (49.0 to 81.4)70.9 (62.9 to 78.1)70.1 (62.9 to 76.6)
Pain: moderate (n = 32, 116, 148)53.1 (34.7 to 70.9)27.6 (19.7 to 36.7)33.1 (25.6 to 41.3)
Pain: severe (n = 27, 104, 131)14.8 (4.2 to 33.7)1.9 (0.2 to 6.8)4.6 (1.7 to 9.7)
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 3

Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).

Time frame:
Within 14 days after 13vPnC Dose 3
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 3
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Redness: any (n = 25, 95, 120)32.0 (14.9 to 53.5)9.5 (4.4 to 17.2)14.2 (8.5 to 21.7)
Redness: mild (n = 24, 94, 118)20.8 (7.1 to 42.2)8.5 (3.7 to 16.1)11.0 (6.0 to 18.1)
Redness: moderate (n = 24, 93, 117)20.8 (7.1 to 42.2)1.1 (0.0 to 5.8)5.1 (1.9 to 10.8)
Redness: severe (n = 23, 93, 116)4.3 (0.1 to 21.9)1.1 (0.0 to 5.8)1.7 (0.2 to 6.1)
Swelling: any (n = 28, 93, 121)35.7 (18.6 to 55.9)8.6 (3.8 to 16.2)14.9 (9.1 to 22.5)
Swelling: mild (n = 27, 93, 120)25.9 (11.1 to 46.3)8.6 (3.8 to 16.2)12.5 (7.2 to 19.8)
Swelling: moderate (n = 25, 92, 117)20.0 (6.8 to 40.7)0.0 (0.0 to 3.9)4.3 (1.4 to 9.7)
Swelling: severe (n = 23, 92, 115)4.3 (0.1 to 21.9)0.0 (0.0 to 3.9)0.9 (0.0 to 4.7)
Pain: any (n = 37, 138, 175)70.3 (53.0 to 84.1)73.2 (65.0 to 80.4)72.6 (65.3 to 79.0)
Pain: mild (n = 31, 132, 163)64.5 (45.4 to 80.8)67.4 (58.7 to 75.3)66.9 (59.1 to 74.0)
Pain: moderate (n = 34, 107, 141)38.2 (22.2 to 56.4)27.1 (19.0 to 36.6)29.8 (22.4 to 38.1)
Pain: severe (n = 24, 93, 117)8.3 (1.0 to 27.0)3.2 (0.7 to 9.1)4.3 (1.4 to 9.7)
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 4

Specific local reactions were prompted for each day, and reported using an electronic diary. Redness and Swelling were scaled as Any (redness present or swelling present); Mild (0.5 to 2.0 centimeters \[cm\] for participants aged 2 to \<12 years and 2.5 to 5.0 cm for participants aged \>= 12 years); Moderate (2.5 to 7.0 cm for participants aged 2 to \<12 years and 5.5 to 10.0 cm for participants aged \>= 12 years); Severe (greater than \[\>\] 7.0 cm for participants aged 2 to \<12 years and \>10.0 cm for participants aged \>= 12 years). Pain at injection site was scaled as Any (pain present); Mild (did not interfere with activity); Moderate (interfered with activity); Severe (prevented daily activity).

Time frame:
Within 14 days after 13vPnC Dose 4
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Local Reactions: 13vPnC Dose 4
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Redness: any (n = 21, 79, 100)71.4 (47.8 to 88.7)22.8 (14.1 to 33.6)33.0 (23.9 to 43.1)
Redness: mild (n = 20, 77, 97)50.0 (27.2 to 72.8)15.6 (8.3 to 25.6)22.7 (14.8 to 32.3)
Redness: moderate (n = 18, 72, 90)50.0 (26.0 to 74.0)9.7 (4.0 to 19.0)17.8 (10.5 to 27.3)
Redness: severe (n = 16, 73, 89)12.5 (1.6 to 38.3)4.1 (0.9 to 11.5)5.6 (1.8 to 12.6)
Swelling: any (n = 27, 81, 108)66.7 (46.0 to 83.5)28.4 (18.9 to 39.5)38.0 (28.8 to 47.8)
Swelling: mild (n = 21, 79, 100)38.1 (18.1 to 61.6)21.5 (13.1 to 32.2)25.0 (16.9 to 34.7)
Swelling: moderate (n = 23, 72, 95)52.2 (30.6 to 73.2)6.9 (2.3 to 15.5)17.9 (10.8 to 27.1)
Swelling: severe (n = 15, 73, 88)6.7 (0.2 to 31.9)4.1 (0.9 to 11.5)4.5 (1.3 to 11.2)
Pain: any (n = 30, 113, 143)86.7 (69.3 to 96.2)77.0 (68.1 to 84.4)79.0 (71.4 to 85.4)
Pain: mild (n = 25, 105, 130)76.0 (54.9 to 90.6)71.4 (61.8 to 79.8)72.3 (63.8 to 79.8)
Pain: moderate (n = 24, 85, 109)62.5 (40.6 to 81.2)31.8 (22.1 to 42.8)38.5 (29.4 to 48.3)
Pain: severe (n = 16, 74, 90)12.5 (1.6 to 38.3)5.4 (1.5 to 13.3)6.7 (2.5 to 13.9)
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 1

Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).

Time frame:
Within 14 days after 13vPnC Dose 1
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 1
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Fever: >=38 degrees C (n = 39, 130, 169)12.8 (4.3 to 27.4)6.2 (2.7 to 11.8)7.7 (4.2 to 12.8)
Fever: >=38, <38.5 degrees C (n = 37, 130, 167)5.4 (0.7 to 18.2)6.2 (2.7 to 11.8)6.0 (2.9 to 10.7)
Fever: >=38.5, <39 degrees C (n = 37, 128, 165)5.4 (0.7 to 18.2)0.0 (0.0 to 2.8)1.2 (0.1 to 4.3)
Fever: >=39, =<40 degrees C (n = 39, 128, 167)7.7 (1.6 to 20.9)0.0 (0.0 to 2.8)1.8 (0.4 to 5.2)
Fever: >40 degrees C (n = 37, 128, 165)0.0 (0.0 to 9.5)0.0 (0.0 to 2.8)0.0 (0.0 to 2.2)
Fatigue: Any (n = 45, 159, 204)53.3 (37.9 to 68.3)59.7 (51.7 to 67.4)58.3 (51.2 to 65.2)
Fatigue: Mild (n = 41, 149, 190)36.6 (22.1 to 53.1)49.0 (40.7 to 57.3)46.3 (39.1 to 53.7)
Fatigue: Moderate (n = 44, 148, 192)36.4 (22.4 to 52.2)35.8 (28.1 to 44.1)35.9 (29.2 to 43.2)
Fatigue: Severe (n = 37, 136, 173)10.8 (3.0 to 25.4)11.8 (6.9 to 18.4)11.6 (7.2 to 17.3)
Headache: Any (n = 42, 147, 189)45.2 (29.8 to 61.3)44.2 (36.0 to 52.6)44.4 (37.2 to 51.8)
Headache: Mild (n = 41, 145, 186)39.0 (24.2 to 55.5)37.9 (30.0 to 46.4)38.2 (31.2 to 45.6)
Headache: Moderate (n = 40, 134, 174)20.0 (9.1 to 35.6)17.2 (11.2 to 24.6)17.8 (12.4 to 24.3)
Headache: Severe (n = 37, 130, 167)2.7 (0.1 to 14.2)2.3 (0.5 to 6.6)2.4 (0.7 to 6.0)
Vomiting: Any (n = 39, 134, 173)20.5 (9.3 to 36.5)20.9 (14.4 to 28.8)20.8 (15.0 to 27.6)
Vomiting: Mild (n = 38, 134, 172)18.4 (7.7 to 34.3)17.9 (11.8 to 25.5)18.0 (12.6 to 24.6)
Vomiting: Moderate (n = 38, 128, 166)2.6 (0.1 to 13.8)3.9 (1.3 to 8.9)3.6 (1.3 to 7.7)
Vomiting: Severe (n = 37, 128, 165)5.4 (0.7 to 18.2)0.0 (0.0 to 2.8)1.2 (0.1 to 4.3)
Diarrhea: Any (n = 44, 145, 189)31.8 (18.6 to 47.6)35.9 (28.1 to 44.2)34.9 (28.1 to 42.2)
Diarrhea: Mild (n = 44, 142, 186)31.8 (18.6 to 47.6)33.8 (26.1 to 42.2)33.3 (26.6 to 40.6)
Diarrhea: Moderate (n = 38, 133, 171)5.3 (0.6 to 17.7)9.0 (4.7 to 15.2)8.2 (4.5 to 13.4)
Diarrhea: Severe (n = 37, 131, 168)0.0 (0.0 to 9.5)3.8 (1.3 to 8.7)3.0 (1.0 to 6.8)
Muscle Pain: Any (n = 47, 154, 201)55.3 (40.1 to 69.8)50.0 (41.8 to 58.2)51.2 (44.1 to 58.3)
Muscle Pain: Mild (n = 43, 148, 191)46.5 (31.2 to 62.3)42.6 (34.5 to 51.0)43.5 (36.3 to 50.8)
Muscle Pain: Moderate (n = 44, 139, 183)36.4 (22.4 to 52.2)21.6 (15.1 to 29.4)25.1 (19.0 to 32.1)
Muscle Pain: Severe (n = 37, 131, 168)5.4 (0.7 to 18.2)5.3 (2.2 to 10.7)5.4 (2.5 to 9.9)
Joint Pain: Any (n = 38, 143, 181)26.3 (13.4 to 43.1)26.6 (19.5 to 34.6)26.5 (20.2 to 33.6)
Joint Pain: Mild (n = 37, 139, 176)18.9 (8.0 to 35.2)19.4 (13.2 to 27.0)19.3 (13.8 to 25.9)
Joint Pain: Moderate (n = 38, 137, 175)15.8 (6.0 to 31.3)14.6 (9.2 to 21.6)14.9 (9.9 to 21.0)
Joint Pain: Severe (n = 37, 130, 167)2.7 (0.1 to 14.2)3.1 (0.8 to 7.7)3.0 (1.0 to 6.8)
Use of Medication to Treat Pain (n= 40, 136, 176)25.0 (12.7 to 41.2)13.2 (8.0 to 20.1)15.9 (10.8 to 22.2)
Use of Medication to Treat Fever (n= 41, 133, 174)24.4 (12.4 to 40.3)14.3 (8.8 to 21.4)16.7 (11.5 to 23.1)
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 2

Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).

Time frame:
Within 14 days after 13vPnC Dose 2
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 2
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Fever: >=38 degrees C (n = 26, 105, 131)23.1 (9.0 to 43.6)6.7 (2.7 to 13.3)9.9 (5.4 to 16.4)
Fever: >=38, <38.5 degrees C (n = 26, 105, 131)19.2 (6.6 to 39.4)5.7 (2.1 to 12.0)8.4 (4.3 to 14.5)
Fever: >=38.5, <39 degrees C (n = 24, 102, 126)8.3 (1.0 to 27.0)1.0 (0.0 to 5.3)2.4 (0.5 to 6.8)
Fever: >=39, =<40 degrees C (n = 24, 102, 126)8.3 (1.0 to 27.0)1.0 (0.0 to 5.3)2.4 (0.5 to 6.8)
Fever: >40 degrees C (n = 24, 102, 126)0.0 (0.0 to 14.2)0.0 (0.0 to 3.6)0.0 (0.0 to 2.9)
Fatigue: Any (n = 38, 133, 171)60.5 (43.4 to 76.0)56.4 (47.5 to 65.0)57.3 (49.5 to 64.8)
Fatigue: Mild (n = 31, 125, 156)45.2 (27.3 to 64.0)39.2 (30.6 to 48.3)40.4 (32.6 to 48.5)
Fatigue: Moderate (n = 33, 122, 155)45.5 (28.1 to 63.6)37.7 (29.1 to 46.9)39.4 (31.6 to 47.5)
Fatigue: Severe (n = 24, 107, 131)12.5 (2.7 to 32.4)9.3 (4.6 to 16.5)9.9 (5.4 to 16.4)
Headache: Any (n = 31, 121,152)32.3 (16.7 to 51.4)35.5 (27.0 to 44.8)34.9 (27.3 to 43.0)
Headache: Mild (n = 30, 117, 147)30.0 (14.7 to 49.4)29.9 (21.8 to 39.1)29.9 (22.7 to 38.0)
Headache: Moderate (n = 26, 110, 136)7.7 (0.9 to 25.1)16.4 (10.0 to 24.6)14.7 (9.2 to 21.8)
Headache: Severe (n = 24, 104, 128)0.0 (0.0 to 14.2)1.9 (0.2 to 6.8)1.6 (0.2 to 5.5)
Vomiting: Any (n = 28, 107, 135)21.4 (8.3 to 41.0)13.1 (7.3 to 21.0)14.8 (9.3 to 21.9)
Vomiting: Mild (n = 27, 107, 134)18.5 (6.3 to 38.1)10.3 (5.2 to 17.7)11.9 (7.0 to 18.7)
Vomiting: Moderate (n = 28, 103, 131)14.3 (4.0 to 32.7)4.9 (1.6 to 11.0)6.9 (3.2 to 12.6)
Vomiting: Severe (n = 24, 102, 126)0.0 (0.0 to 14.2)1.0 (0.0 to 5.3)0.8 (0.0 to 4.3)
Diarrhea: Any (n = 29, 121, 150)31.0 (15.3 to 50.8)28.9 (21.0 to 37.9)29.3 (22.2 to 37.3)
Diarrhea: Mild (n = 29, 120, 149)31.0 (15.3 to 50.8)26.7 (19.0 to 35.5)27.5 (20.5 to 35.4)
Diarrhea: Moderate (n = 25, 109, 134)8.0 (1.0 to 26.0)10.1 (5.1 to 17.3)9.7 (5.3 to 16.0)
Diarrhea: Severe (n = 24, 103, 127)0.0 (0.0 to 14.2)1.9 (0.2 to 6.8)1.6 (0.2 to 5.6)
Muscle Pain: Any (n = 36, 124, 160)44.4 (27.9 to 61.9)45.2 (36.2 to 54.3)45.0 (37.1 to 53.1)
Muscle Pain: Mild (n = 32, 118, 150)31.3 (16.1 to 50.0)37.3 (28.6 to 46.7)36.0 (28.3 to 44.2)
Muscle Pain: Moderate (n = 32, 111, 143)37.5 (21.1 to 56.3)25.2 (17.5 to 34.4)28.0 (20.8 to 36.1)
Muscle Pain: Severe (n = 25, 106, 131)8.0 (1.0 to 26.0)5.7 (2.1 to 11.9)6.1 (2.7 to 11.7)
Joint Pain: Any (n = 31, 116, 147)32.3 (16.7 to 51.4)23.3 (15.9 to 32.0)25.2 (18.4 to 33.0)
Joint Pain: Mild (n = 27, 115, 142)18.5 (6.3 to 38.1)21.7 (14.6 to 30.4)21.1 (14.7 to 28.8)
Joint Pain: Moderate (n = 30, 106, 136)30.0 (14.7 to 49.4)10.4 (5.3 to 17.8)14.7 (9.2 to 21.8)
Joint Pain: Severe (n = 25, 104, 129)4.0 (0.1 to 20.4)1.9 (0.2 to 6.8)2.3 (0.5 to 6.6)
Use of Medication to Treat Pain (n= 28, 105, 133)25.0 (10.7 to 44.9)7.6 (3.3 to 14.5)11.3 (6.5 to 17.9)
Use of Medication to Treat Fever (n= 27, 107, 134)33.3 (16.5 to 54.0)10.3 (5.2 to 17.7)14.9 (9.4 to 22.1)
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 3

Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).

Time frame:
Within 14 days after 13vPnC Dose 3
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 3
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Fever: >=38 degrees C (n = 27, 93, 120)14.8 (4.2 to 33.7)4.3 (1.2 to 10.6)6.7 (2.9 to 12.7)
Fever: >=38, <38.5 degrees C (n = 26, 93, 119)11.5 (2.4 to 30.2)3.2 (0.7 to 9.1)5.0 (1.9 to 10.7)
Fever: >=38.5, <39 degrees C (n = 24, 93, 117)4.2 (0.1 to 21.1)3.2 (0.7 to 9.1)3.4 (0.9 to 8.5)
Fever: >=39, =<40 degrees C (n = 24, 92, 116)4.2 (0.1 to 21.1)1.1 (0.0 to 5.9)1.7 (0.2 to 6.1)
Fever: >40 degrees C (n = 23, 92, 115)0.0 (0.0 to 14.8)0.0 (0.0 to 3.9)0.0 (0.0 to 3.2)
Fatigue: Any (n = 35, 122, 157)48.6 (31.4 to 66.0)49.2 (40.0 to 58.4)49.0 (41.0 to 57.1)
Fatigue: Mild (n = 32, 116, 148)40.6 (23.7 to 59.4)38.8 (29.9 to 48.3)39.2 (31.3 to 47.5)
Fatigue: Moderate (n = 30, 107, 137)33.3 (17.3 to 52.8)29.9 (21.4 to 39.5)30.7 (23.1 to 39.1)
Fatigue: Severe (n = 24, 96, 120)4.2 (0.1 to 21.1)7.3 (3.0 to 14.4)6.7 (2.9 to 12.7)
Headache: Any (n = 32, 110,142)37.5 (21.1 to 56.3)37.3 (28.2 to 47.0)37.3 (29.4 to 45.8)
Headache: Mild (n = 30, 108, 138)30.0 (14.7 to 49.4)32.4 (23.7 to 42.1)31.9 (24.2 to 40.4)
Headache: Moderate (n = 27, 95, 122)22.2 (8.6 to 42.3)15.8 (9.1 to 24.7)17.2 (11.0 to 25.1)
Headache: Severe (n = 25, 94, 119)8.0 (1.0 to 26.0)2.1 (0.3 to 7.5)3.4 (0.9 to 8.4)
Vomiting: Any (n = 25, 95, 120)8.0 (1.0 to 26.0)11.6 (5.9 to 19.8)10.8 (5.9 to 17.8)
Vomiting: Mild (n = 24, 95, 119)4.2 (0.1 to 21.1)5.3 (1.7 to 11.9)5.0 (1.9 to 10.7)
Vomiting: Moderate (n = 24, 93, 117)4.2 (0.1 to 21.1)7.5 (3.1 to 14.9)6.8 (3.0 to 13.0)
Vomiting: Severe (n = 23, 92, 115)0.0 (0.0 to 14.8)0.0 (0.0 to 3.9)0.0 (0.0 to 3.2)
Diarrhea: Any (n = 26, 104, 130)15.4 (4.4 to 34.9)25.0 (17.0 to 34.4)23.1 (16.1 to 31.3)
Diarrhea: Mild (n = 26, 102, 128)15.4 (4.4 to 34.9)21.6 (14.0 to 30.8)20.3 (13.7 to 28.3)
Diarrhea: Moderate (n = 24, 95, 119)4.2 (0.1 to 21.1)5.3 (1.7 to 11.9)5.0 (1.9 to 10.7)
Diarrhea: Severe (n = 23, 94, 117)0.0 (0.0 to 14.8)2.1 (0.3 to 7.5)1.7 (0.2 to 6.0)
Muscle Pain: Any (n = 35, 117, 152)45.7 (28.8 to 63.4)38.5 (29.6 to 47.9)40.1 (32.3 to 48.4)
Muscle Pain: Mild (n = 30, 112, 142)33.3 (17.3 to 52.8)33.0 (24.4 to 42.6)33.1 (25.4 to 41.5)
Muscle Pain: Moderate (n = 31, 101, 132)32.3 (16.7 to 51.4)16.8 (10.1 to 25.6)20.5 (13.9 to 28.3)
Muscle Pain: Severe (n = 24, 94, 118)4.2 (0.1 to 21.1)3.2 (0.7 to 9.0)3.4 (0.9 to 8.5)
Joint Pain: Any (n = 28, 104, 132)25.0 (10.7 to 44.9)20.2 (13.0 to 29.2)21.2 (14.6 to 29.2)
Joint Pain: Mild (n = 26, 102, 128)19.2 (6.6 to 39.4)17.6 (10.8 to 26.4)18.0 (11.7 to 25.7)
Joint Pain: Moderate (n = 27, 95, 122)18.5 (6.3 to 38.1)8.4 (3.7 to 15.9)10.7 (5.8 to 17.5)
Joint Pain: Severe (n = 25, 94, 119)8.0 (1.0 to 26.0)2.1 (0.3 to 7.5)3.4 (0.9 to 8.4)
Use of Medication to Treat Pain (n= 28, 97, 125)21.4 (8.3 to 41.0)12.4 (6.6 to 20.6)14.4 (8.8 to 21.8)
Use of Medication to Treat Fever (n= 30, 101, 131)26.7 (12.3 to 45.9)15.8 (9.3 to 24.4)18.3 (12.1 to 26.0)
Other pre-specifiedPercentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 4

Specific systemic events (fever \>=38 degrees Celsius \[C\], fatigue, headache, vomiting, diarrhea, muscle pain, joint pain and use of medication to treat pain/fever) were prompted for each day, and reported using an electronic diary. Fatigue, headache, muscle pain and joint pain were scaled as: Any (symptom present); Mild (did not interfere with activity); Moderate (some interference with activity); Severe (prevented routine daily activity). Vomiting was scaled as: Any (vomiting present); Mild (1-2 times in 24 hours); Moderate (\>2 times in 24 hours); Severe (required intravenous hydration). Diarrhea was scaled as: Any (diarrhea present); Mild (2-3 loose stools in 24 hours); Moderate (4-5 loose stools 24 hours); Severe (\>=6 loose stools in 24 hours).

Time frame:
Within 14 days after 13vPnC Dose 4
Reported as:
Number · percentage of participants
Percentage of Pediatric, Adult and All Participants Reporting Pre-specified Systemic Events: 13vPnC Dose 4
percentage of participants13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)13vPnC, 23vPS (All Participants)
Fever: >=38 degrees C (n= 18, 78, 96)27.8 (9.7 to 53.5)15.4 (8.2 to 25.3)17.7 (10.7 to 26.8)
Fever: >=38, <38.5 degrees C (n = 16, 76, 92)12.5 (1.6 to 38.3)13.2 (6.5 to 22.9)13.0 (6.9 to 21.7)
Fever: >=38.5, <39 degrees C (n = 17, 73, 90)17.6 (3.8 to 43.4)2.7 (0.3 to 9.5)5.6 (1.8 to 12.5)
Fever: >=39, =<40 degrees C (n = 15, 72, 87)0.0 (0.0 to 21.8)2.8 (0.3 to 9.7)2.3 (0.3 to 8.1)
Fever: >40 degrees C (n = 15, 71, 86)0.0 (0.0 to 21.8)0.0 (0.0 to 5.1)0.0 (0.0 to 4.2)
Fatigue: Any (n = 28, 100, 128)67.9 (47.6 to 84.1)67.0 (56.9 to 76.1)67.2 (58.3 to 75.2)
Fatigue: Mild (n = 26, 95, 121)61.5 (40.6 to 79.8)54.7 (44.2 to 65.0)56.2 (46.9 to 65.2)
Fatigue: Moderate (n = 20, 86, 106)45.0 (23.1 to 68.5)45.3 (34.6 to 56.5)45.3 (35.6 to 55.2)
Fatigue: Severe (n = 16, 77, 93)12.5 (1.6 to 38.3)13.0 (6.4 to 22.6)12.9 (6.8 to 21.5)
Headache: Any (n = 21, 93, 114)52.4 (29.8 to 74.3)45.2 (34.8 to 55.8)46.5 (37.1 to 56.1)
Headache: Mild (n = 21, 88, 109)47.6 (25.7 to 70.2)38.6 (28.4 to 49.6)40.4 (31.1 to 50.2)
Headache: Moderate (n = 16, 82, 98)18.8 (4.0 to 45.6)28.0 (18.7 to 39.1)26.5 (18.1 to 36.4)
Headache: Severe (n = 16, 74, 90)12.5 (1.6 to 38.3)5.4 (1.5 to 13.3)6.7 (2.5 to 13.9)
Vomiting: Any (n = 16, 73, 89)6.3 (0.2 to 30.2)5.5 (1.5 to 13.4)5.6 (1.8 to 12.6)
Vomiting: Mild (n = 16, 73, 89)6.3 (0.2 to 30.2)5.5 (1.5 to 13.4)5.6 (1.8 to 12.6)
Vomiting: Moderate (n = 15, 71, 86)0.0 (0.0 to 21.8)0.0 (0.0 to 5.1)0.0 (0.0 to 4.2)
Vomiting: Severe (n = 15, 71, 86)0.0 (0.0 to 21.8)0.0 (0.0 to 5.1)0.0 (0.0 to 4.2)
Diarrhea: Any (n = 18, 83, 101)22.2 (6.4 to 47.6)30.1 (20.5 to 41.2)28.7 (20.1 to 38.6)
Diarrhea: Mild (n = 18, 82, 100)22.2 (6.4 to 47.6)29.3 (19.7 to 40.4)28.0 (19.5 to 37.9)
Diarrhea: Moderate (n = 15, 72, 87)0.0 (0.0 to 21.8)4.2 (0.9 to 11.7)3.4 (0.7 to 9.7)
Diarrhea: Severe (n = 15, 72, 87)0.0 (0.0 to 21.8)1.4 (0.0 to 7.5)1.1 (0.0 to 6.2)
Muscle Pain: Any (n = 24, 99, 123)58.3 (36.6 to 77.9)60.6 (50.3 to 70.3)60.2 (50.9 to 68.9)
Muscle Pain: Mild (n = 22, 92, 114)50.0 (28.2 to 71.8)50.0 (39.4 to 60.6)50.0 (40.5 to 59.5)
Muscle Pain: Moderate (n = 19, 80, 99)36.8 (16.3 to 61.6)30.0 (20.3 to 41.3)31.3 (22.4 to 41.4)
Muscle Pain: Severe (n = 16, 75, 91)12.5 (1.6 to 38.3)6.7 (2.2 to 14.9)7.7 (3.1 to 15.2)
Joint Pain: Any (n = 16, 83, 99)25.0 (7.3 to 52.4)32.5 (22.6 to 43.7)31.3 (22.4 to 41.4)
Joint Pain: Mild (n = 15, 78, 93)13.3 (1.7 to 40.5)24.4 (15.3 to 35.4)22.6 (14.6 to 32.4)
Joint Pain: Moderate (n = 16, 75, 91)12.5 (1.6 to 38.3)17.3 (9.6 to 27.8)16.5 (9.5 to 25.7)
Joint Pain: Severe (n = 16, 74, 90)6.3 (0.2 to 30.2)4.1 (0.8 to 11.4)4.4 (1.2 to 11.0)
Use of Medication to Treat Pain (n= 16, 77, 93)18.8 (4.0 to 45.6)16.9 (9.3 to 27.1)17.2 (10.2 to 26.4)
Use of Medication to Treat Fever (n= 17, 77, 94)23.5 (6.8 to 49.9)15.6 (8.3 to 25.6)17.0 (10.1 to 26.2)

Adverse events

Collected over AEs/SAEs: recorded from 13vPnC Dose 1 to completion of study. Participants recorded pre-specified AEs in electronic diary:local reactions; systemic events (up to 14 days after 13vPnC vaccination). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
13vPnC Dose 1 to 13vPnC Dose 3 Blood Draw—58/247 (23.5%)203/247 (82.2%)
13vPnC Dose 3 Blood Draw to 13vPnC Dose 4—42/221 (19%)89/221 (40.3%)
13vPnC Dose 4—11/192 (5.7%)127/192 (66.1%)
23vPS Dose—11/184 (6%)93/184 (50.5%)
Follow-up—28/247 (11.3%)19/247 (7.7%)
Most frequent serious events
Showing 10 of 123
Most frequent serious events
Event13vPnC Dose 1 to 13vPnC Dose 3 Blood Draw13vPnC Dose 3 Blood Draw to 13vPnC Dose 413vPnC Dose 423vPS DoseFollow-up
PyrexiaGeneral disorders6/2474/2210/1920/1844/247
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/2472/2210/1920/1840/247
Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)6/2474/2211/1920/1843/247
Graft versus host diseaseImmune system disorders5/2471/2210/1920/1842/247
Herpes zosterInfections and infestations2/2474/2211/1921/1842/247
PneumoniaInfections and infestations2/2472/2211/1920/1844/247
Graft versus host disease in liverImmune system disorders1/2471/2210/1922/1840/247
Graft versus host disease in skinImmune system disorders1/2472/2210/1920/1840/247
Escherichia sepsisInfections and infestations2/2472/2210/1920/1840/247
Bronchopulmonary aspergillosisInfections and infestations1/2472/2210/1920/1840/247
Most frequent other events
Showing 10 of 544
Most frequent other events
Event13vPnC Dose 1 to 13vPnC Dose 3 Blood Draw13vPnC Dose 3 Blood Draw to 13vPnC Dose 413vPnC Dose 423vPS DoseFollow-up
Pain (Any)Skin and subcutaneous tissue disorders165/222—113/143——
Pain (Any)Skin and subcutaneous tissue disorders146/194————
Pain (Any)Skin and subcutaneous tissue disorders127/175————
Pain (Mild)Skin and subcutaneous tissue disorders151/217—94/130——
Pain (Mild)Skin and subcutaneous tissue disorders129/184————
Fatigue (Any)General disorders119/204—86/128——
Pain (Mild)Skin and subcutaneous tissue disorders109/163————
Muscle pain (Any)General disorders103/201—74/123——
Fatigue (Any)General disorders98/171————
Fatigue (Mild)General disorders88/190—68/121——

Baseline characteristics

Safety population included all participants who received at least 1 dose of investigational product and had safety data available.

Age, Continuous
Age, Continuous(years)13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)Total
Mean10.3 ± 4.4147.3 ± 12.3938.4 ± 19.26
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC, 23vPS (Pediatric Participants)13vPnC, 23vPS (Adult Participants)Total
Female2674100
Male33114147
08

Study locations

47 sites
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Steven and Alexandra Cohen Children's Medical Center of New York
    New Hyde Park, New York 11040, United States
  • Columbia University Medical Center Research Pharmacy
    New York, New York 10032, United States
  • Columbia University Medical Center-Presbyterian Hospital Building
    New York, New York 10032, United States
  • Columbia University/Taub Institute Irving Center for Clinical Research
    New York, New York 10032, United States
  • New York-Presbyterian Morgan Stanley Children's Hospital
    New York, New York 10032, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Universitair Ziekenhuis Gent
    Belgium, 9000, Belgium
  • Algemeen Ziekenhuis St.-Jan A.V.
    Brugge, 8000, Belgium
  • Clinical University St Luc
    Brussels, 1200, Belgium
  • Universitaire Ziekenhuizen Leuven (UZ) Gasthuisberg
    Leuven, 3000, Belgium
  • CHU Liege
    Liege, 4000, Belgium
  • CancerCare Manitoba
    Winnipeg, Manitoba R3E 0V9, Canada
  • Hopital Maisonneuve-Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Fakultni nemocnice Brno/Interni hematoonkologicka klinika
    Bmo, 625 00, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, 15006, Czechia
  • Hôpital Jean Minjoz
    Besancon, 25000, France
  • Hopital Henri Mondor
    Créteil, 94000, France
  • Hôpital Henri Mondor, Pharmacie
    Créteil, 94010, France
  • Hopital Saint-Louis
    PARIS Cedex 10, 75475, France
  • Hopital Robert Debre
    Paris Cedex 19, 75019, France
  • Hopital Robert Debre - Service Pharmacie
    PARIS Cedex 19, 75935, France
  • Hôpital Saint Louis
    Paris, 75010, France
  • CHRU Robert Debré
    Paris, 75019, France
  • Charite Universitaetsmedizin
    Berlin, 13353, Germany
  • Clinical Trial Center North MediGate GmbH
    Hamburg, 20246, Germany
  • Klinik und Poliklinik fuer Paediatrische Haematologie und Onkologie
    Hamburg, 20246, Germany
  • Universitaetsklinikum Hamburg Eppendorf Clinical Trial Center North MediGate GmbH
    Hamburg, 20246, Germany
  • Universitaetsklinikum Hamburg-Eppendorf, Onkologisches Zentrum
    Hamburg, 20246, Germany
  • Universitatsklinikum Jena
    Jena, 07740, Germany
  • "Universitaetsklinikum Muenster,
    Muenster, 48149, Germany
  • Universitaetsklinikum Muenster
    Muenster, 48149, Germany
  • UMC Utrecht, Wilhelmina Kinder Ziekenhuis
    Utrecht, 3584 EA, Netherlands
  • Klinika Hematologii i Transplantologii
    Gdansk, 80-952, Poland
  • NZOZ "HIPOKRATES-II" Sp. z o.o.
    Krakow, 31-223, Poland
  • Klinika Transplantacji Szpiku, Onkologii i Hematologii Dzieciecej
    Wroclaw, 50-345, Poland
  • Hospital Universitario La Princesa
    Madrid, 28006, Spain
  • Hospital Universitario Infantil Niño Jesús
    Madrid, 28009, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitari i Politecnic La Fe de Valencia
    Valencia, 46026, Spain
  • Sahlgrenska Universitetssjukhuset
    Goteborg, 413 45, Sweden
  • Karolinska Universitetssjukhuset Huddinge
    Huddinge, 141 86, Sweden
  • Universitetssjukhuset i Lund, Barnonkologen Avd 64
    Lund, 221 85, Sweden
  • Karolinska University Hospital Huddinge
    Stockholm, 141 86, Sweden
  • Akademiska Sjukhuset, Infektionskliniken
    Uppsala, 751 85, Sweden
09

References and documents

Publications

  • Cordonnier C, Ljungman P, Juergens C, Maertens J, Selleslag D, Sundaraiyer V, Giardina PC, Clarke K, Gruber WC, Scott DA, Schmoele-Thoma B; 3003 Study Group. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged >/=2 years: an open-label study. Clin Infect Dis. 2015 Aug 1;61(3):313-23. doi: 10.1093/cid/civ287. Epub 2015 Apr 13. PubMed 25870329 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2010 to primary completion in May 2013, 39 months.

Results were first posted in Apr 2014, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2009
First posted
Sep 21, 2009
StartActual
Jan 18, 2010
Primary completionActual
May 16, 2013
CompletionActual
May 16, 2013
Results first posted
Apr 21, 2014
Last update
Dec 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00980655
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Sep 21, 2009
Start date
Jan 18, 2010
Primary completion
May 16, 2013
Completion
May 16, 2013
Results posted
Apr 21, 2014
Last update
Dec 20, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion